The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C.
The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C.
复制标题
DOI：
10.3390/v14030474
复制
发表时间：
2022-02-25
期刊：
影响因子：
--
通讯作者：
Marczyńska M
中科院分区：
文献类型：
--
作者：
Pokorska-Śpiewak M;Dobrzeniecka A;Marczyńska M
Background: There are limited data available on the influence of direct-acting antivirals used to treat chronic hepatitis C (CHC) on growth in children. In this study, we aimed to analyze the growth parameters in children treated with ledipasvir/sofosbuvir (LDV/SOF). Methods: We included 38 patients (16 girls and 22 boys) aged 10–17 years treated with LDV/SOF for CHC (33 infected with genotype 1 and 5 with genotype 4; 36 were treated for 12 weeks, and 2 for 24 weeks according to the current guidelines). Patient weight and height were measured at baseline, after 4 weeks of treatment, at the end of the treatment (EOT), and 12 weeks and one year after the EOT. Body mass index (BMI), BMI z and height-for-age (HA) z scores were calculated according to the WHO Child Growth Standards and Growth reference data using the WHO anthropometric calculator AnthroPlus v. 1.0.4. In addition, correlations between BMI z scores and liver fibrosis (liver stiffness measurement, LSM), the aspartate transaminase (AST)-to-platelet ratio index (APRI), fibrosis-4 index (FIB-4) and liver steatosis (controlled attenuation parameter, CAP) were analyzed. Results: At baseline, 5/38 (13%) patients were obese (BMI z score > 2 SD), 4/38 (11%) were overweight, and 29 (76%) were normal. A significant increase was observed in mean weight, height and BMI both 12 weeks and one year after the treatment compared to the baseline, whereas no differences were observed for BMI z scores and HA z scores. Baseline BMI z scores correlated with alanine aminotransferase levels (r = 0.33, 95% CI 0.01–0.58, p = 0.04), LSM (r = 0.40, 95% CI 0.09–0.65, p = 0.01), the APRI (r = 0.33, 95% CI 0.02–0.59, p = 0.03), and the CAP (r = 0.40, 95% CI 0.08–0.64, p = 0.01). No similar correlations were reported at 12 weeks posttreatment. Conclusions: Treatment with LDV/SOF in children with CHC (genotypes 1 and 4) did not negatively influence the patients’ growth. However, higher baseline BMI z scores correlated with more advanced liver fibrosis and steatosis in children with CHC.
登录
查看更多内容
影响因子：
13.5
作者：
Jonas, Maureen M.;Balistreri, William;Gonzalez-Peralta, Regino P.;Haber, Barbara;Lobritto, Steven;Mohan, Parvathi;Molleston, Jean P.;Murray, Karen F.;Narkewicz, Michael R.;Rosenthal, Philip;Schwarz, Kathleen B.;Barton, Bruce A.;Shepherd, John A.;Mitchell, Paul D.;Duggan, Christopher
通讯作者：
Duggan, Christopher
影响因子：
3.9
作者：
Pokorska-Śpiewak M;Dobrzeniecka A;Aniszewska M;Marczyńska M
通讯作者：
Marczyńska M
影响因子：
13.5
作者：
Lin, Zhong-Hua;Xin, Yong-Ning;Xuan, Shi-Ying
通讯作者：
Xuan, Shi-Ying
影响因子：
5.1
作者：
Mogahed, Engy A.;El-Karaksy, Hanaa;El-Raziky, Mona S.
通讯作者：
El-Raziky, Mona S.
DOI：
10.1097/mpg.0000000000001872
发表时间：
2018-03-01
影响因子：
2.9
作者：
Indolfi, Giuseppe;Hierro, Loreto;Fischler, Bjorn
通讯作者：
Fischler, Bjorn